S. Basili (1), V. Raparelli (1), A. Vestri (1), G. L. Di Tanna (1), F. Violi (1)
(1) Internal Medicine Division – Atherothrombosis Centre and BioMedical Statistics and Clinical Epidemiology Centre, Department of Experimental Medicine, “La Sapienza” University of Rome, Italy
It was the aim of the present study to investigate if antiplatelet treatment reduced cardiovascular events in patients with claudication and/or an ankle/brachial index (ABI)≤0.99 and to analyse if specific antiplatelet treatment had a different impact on clinical outcome. We performed a meta-analysis of 29 clinical randomized trials on antiplatelet therapy for prevention of vascular death, myocardial infarction, and stroke in 10,735 peripheral artery disease patients. The primary end-point utilizing in the meta-analysis construction was Cardiovascular Adverse Event. We found 1,900 (17.70%) patients in trials with aspirin, 5,326 (49.61%) in those with thienopyridines, 2,324 (21.65%) in those with picotamide and 1,185 (11.04 %) in those with others antiplatelet drugs. A statistically significant effect of antiplatelet treatment [odds ratio (OR) 0.839; 95% confidence interval (CI) 0.729–0.965; p=0.014] was observed. There was a statistically significant reduction of clinical outcome [OR 0.779; 95% CI 0.639–0.950; p=0.014] in the thienopyridine-treated group vs. control. Patients treated with picotamide [OR 0.785; 95% CI 0.495–1.243; p=0.302] or aspirin [OR 0.847; 95%CI 0.653–1.097; p=0.084] showed reduced cardiovascular outcomes, that, however, did not reach significance. The study confirms that antiplatelet treatment reduces vascular outcome in claudicants. Significant reduction was observed with thienopyridines while data regarding aspirin and picotamide were inconclusive.
Atherosclerosis, Clinical trials, antiplatelet drugs, atherothrombosis, Antiplatelet agents, vasculopathies
Andreas E. May, Tobias Geisler, Meinrad Gawaz
Thromb Haemost 2008 99 3: 487-493
Christian Schulz1, Ildiko Konrad1, Susanne Sauer1, Lena Orschiedt1, Maria Koellnberger1, Reinhard Lorenz2, Ulrich Walter3, Steffen Massberg1,4
Thromb Haemost 2008 99 1: 190-195
E. L. Grove (1), R. Hossain (2), R. F. Storey (2)
Thromb Haemost 2013 109 5: 817-824
Women with atrial fibrillation have a much higher risk for thromboembolic stroke than men suffering...
Atrial fibrillation is the commonest heart rhythm condition. Women with atrial fibrillation...
Prothrombin complex concentrates (PCC) can rapidly normalise prolonged prothrombin time, induced...